These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7923135)

  • 21. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
    Cao S; Frank C; Shirasaka T; Rustum YM
    Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-histidinol on the metabolism of 5-fluorouracil in the BALB/c x DBA/8 F1 murine tumor system.
    Sawyer RC; Stolfi RL; Martin DS
    Cancer Res; 1988 Dec; 48(23):6664-8. PubMed ID: 2460227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzymes of uracil catabolism in normal and neoplastic human tissues.
    Naguib FN; el Kouni MH; Cha S
    Cancer Res; 1985 Nov; 45(11 Pt 1):5405-12. PubMed ID: 3931905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
    Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
    Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.
    Moran RG; Scanlon KL
    Cancer Res; 1991 Sep; 51(17):4618-23. PubMed ID: 1831402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
    Grem JL; Fischer PH
    Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
    Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
    Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
    Darnowski JW; Handschumacher RE
    Cancer Res; 1985 Nov; 45(11 Pt 1):5364-8. PubMed ID: 4053009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.
    Darnowski JW; Sawyer RC; Stolfi RL; Martin DS; Lau-Cam CA
    Cancer Chemother Pharmacol; 1985; 14(1):63-9. PubMed ID: 3965161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
    Diasio RB; Schuetz JD; Wallace HJ; Sommadossi JP
    Cancer Res; 1985 Oct; 45(10):4900-3. PubMed ID: 3928143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
    Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
    Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of the chemotherapeutic agent 5-fluorouracil with an inhibitor of its catabolism results in increased micronucleus induction.
    Stopper H; Kühnel A; Podschun B
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1124-30. PubMed ID: 8093030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon.
    Stolfi RL; Martin DS
    J Biol Response Mod; 1985 Dec; 4(6):634-9. PubMed ID: 2418161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
    Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
    Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
    J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
    Au JL; Rustum YM; Ledesma EJ; Mittelman A; Creaven PJ
    Cancer Res; 1982 Jul; 42(7):2930-7. PubMed ID: 6211226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
    Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
    Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.